Rycarfa 100 mg tabl. Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rycarfa 100 mg tabl.

krka d.d. novo mesto d.d. - carprofen 100 mg - tablet - 100 mg - carprofen 100 mg - carprofen - dog

Rycarfa 50 mg/ml inj. sol. i.v./s.c. vial Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rycarfa 50 mg/ml inj. sol. i.v./s.c. vial

krka d.d. novo mesto d.d. - carprofen 50 mg/ml - solution for injection - 50 mg/ml - carprofen 50 mg/ml - carprofen - dog; cat

POUDRE D'HERBAGES ANTISEPTIQUE NO 533 POWDER Canada - engleză - Health Canada

poudre d'herbages antiseptique no 533 powder

herbes universelles inc. - cinchona officinalis; quercus alba; carya alba - powder - 300mg; 500mg; 200mg - cinchona officinalis 300mg; quercus alba 500mg; carya alba 200mg - herbs and natural products

PEPPERTREE POLLEN MIX- schinus molle, schinus terebinthifolia solution
HICKORY POLLEN MIX- carya glabra, carya ovata, carya lac Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

peppertree pollen mix- schinus molle, schinus terebinthifolia solution hickory pollen mix- carya glabra, carya ovata, carya lac

greer laboratories, inc. - schinus terebinthifolia pollen (unii: 21mid214d4) (schinus terebinthifolia pollen - unii:21mid214d4), schinus molle pollen (unii: m0g28fh9k1) (schinus molle pollen - unii:m0g28fh9k1) - non-standardized allergenic extracts are indicated for: - skin test diagnosis of patients with a clinical history of allergies to one or more of the specific non-standardized allergens. - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by appropriate positive skin tests or by in vitro testing for allergen-specific ige antibodies. food extracts have not been proven safe or effective in allergen immunotherapy. non-standardized allergenic extracts are contraindicated in patients with: - severe, unstable or uncontrolled asthma - history of any severe systemic or local allergic reaction to an allergen extract 8.1 pregnancy risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. there are no human or animal data to establish the presence or absence of non-standardized alle

TREATMENT SET TS340074 injection, solution
TREATMENT SET TS340153 injection, solution
TREATMENT SET TS340525 injection, soluti Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

treatment set ts340074 injection, solution treatment set ts340153 injection, solution treatment set ts340525 injection, soluti

antigen laboratories, inc. - felis catus hair (unii: 1564hd0n96) (felis catus hair - unii:1564hd0n96), cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), carya alba pollen (unii: g2a764t54b) (carya tomentosa pollen - unii:g2a764t54b), dermatophagoides farinae (unii: pr9u2ypf3q) (dermatophagoides farinae - unii:pr9u2ypf3q), dermatophagoides pteronyssinus (unii: 57l1z5378k) (dermatophagoides pte - felis catus hair 400 [bau] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

TREATMENT SET TS345463 injection, solution
TREATMENT SET TS345476 injection, solution
TREATMENT SET TS345694 injection, soluti Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

treatment set ts345463 injection, solution treatment set ts345476 injection, solution treatment set ts345694 injection, soluti

antigen laboratories, inc. - cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10), carya illinoinensis pollen (unii: pyo4jr720y) (carya illinoinensis pollen - unii:pyo4jr720y), carya tomentosa pollen (unii: g2a764t54b) (carya tomentosa pollen - unii:g2a764t54b), amaranthus retroflexus pollen (unii: 73b14px5fw) (amaranthus retroflexus pollen - unii:73b14px5fw), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), rumex acetosella pollen (unii: n52miq - cynodon dactylon pollen 16 [bau] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

TREATMENT SET TS335061 injection, solution
TREATMENT SET TS335100 injection, solution
TREATMENT SET TS335101 injection, soluti Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

treatment set ts335061 injection, solution treatment set ts335100 injection, solution treatment set ts335101 injection, soluti

antigen laboratories, inc. - amaranthus retroflexus pollen (unii: 73b14px5fw) (amaranthus retroflexus pollen - unii:73b14px5fw), salsola kali pollen (unii: 2mh135kc6g) (salsola kali pollen - unii:2mh135kc6g), plantago lanceolata pollen (unii: do87t1u2ci) (plantago lanceolata pollen - unii:do87t1u2ci), carya illinoinensis pollen (unii: pyo4jr720y) (carya illinoinensis pollen - unii:pyo4jr720y), carya alba pollen (unii: g2a764t54b) (carya alba pollen - unii:g2a764t54b), juniperus virginiana pollen (unii: py0ja16r2g) (juniperus virg - amaranthus retroflexus pollen 0.002 g in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

TREATMENT SET TS334972 injection, solution Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

treatment set ts334972 injection, solution

antigen laboratories, inc. - amaranthus retroflexus pollen (unii: 73b14px5fw) (amaranthus retroflexus pollen - unii:73b14px5fw), salsola kali pollen (unii: 2mh135kc6g) (salsola kali pollen - unii:2mh135kc6g), plantago lanceolata pollen (unii: do87t1u2ci) (plantago lanceolata pollen - unii:do87t1u2ci), carya illinoinensis pollen (unii: pyo4jr720y) (carya illinoinensis pollen - unii:pyo4jr720y), carya alba pollen (unii: g2a764t54b) (carya alba pollen - unii:g2a764t54b), juniperus virginiana pollen (unii: py0ja16r2g) (juniperus virg - amaranthus retroflexus pollen 0.0000133 g in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

TREATMENT SET TS336437 injection, solution Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

treatment set ts336437 injection, solution

antigen laboratories, inc. - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), ambrosia trifida pollen (unii: ku1v1898xx) (ambrosia trifida pollen - unii:ku1v1898xx), ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), ambrosia psilostachya pollen (unii: rx18m46k8l) (ambrosia psilostachya pollen - unii:rx18m46k8l), dermatophagoides pteronyssinus (unii: 57l1z5378k) (dermatophagoides pteronyssinus - unii:57l1z5378k), carya alba pollen (unii: g2a764t54b - alternaria alternata 0.002 g in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

ALLERGENIC EXTRACTSINDIVIDUAL TREATMENT VIAL Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

allergenic extractsindividual treatment vial

antigen laboratories, inc. - ambrosia artemisiifolia pollen (unii: k20y81aco3) (ambrosia artemisiifolia pollen - unii:k20y81aco3), cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), sorghum halepense pollen (unii: 577va5b4hp) (sorghum halepense pollen - unii:577va5b4hp), quercus alba pollen (unii: z4y9zsv4kk) (quercus alba pollen - unii:z4y9zsv4kk), carya alba pollen (unii: g2a764t54b) (carya alba pollen - unii:g - ambrosia artemisiifolia pollen 10000 [au] in 1 ml - when the natural exposure to elevated aeroallergens produces symptoms as described under clinical pharmacology, specific diagnosis and therapeutic procedures are indicated. clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. when immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. an orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 this product is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski